Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms
NCT ID: NCT03468244
Last Updated: 2019-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
24 participants
INTERVENTIONAL
2018-05-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer
NCT05192460
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms
NCT06026800
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
NCT06019702
Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer
NCT05227378
Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
NCT05949775
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objectives:
Determine the safety, tolerability and cytokinetics of the personalized mRNA tumor vaccine in patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma.
Secondary objectives:
Make a preliminary evaluation on the efficacy of personalized mRNA tumor vaccine in patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma with the following parameters:
Time of tumor progression (TTP);
Disease Control Rate (DCR);
Objective Remission Rate (ORR);
Overall Survival (OS).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Personalized mRNA Tumor Vaccine
Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma
Personalized mRNA Tumor Vaccine
subcutaneous injection with personalized mRNA tumor vaccine at least four times
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Personalized mRNA Tumor Vaccine
subcutaneous injection with personalized mRNA tumor vaccine at least four times
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma who have disease progression with first line chemotherapy. (1) Failure of treatment is defined as disease progression, recurrence or metastatic disease, or intolerable toxicities occurred after treatment. (2) Each line of treatment during the period of disease progression includes one or more chemotherapy drugs which are administered for not less than one cycle or even longer. Neoadjuvant/adjuvant therapy can be applied at an earlier stage of treatment. If patient has developed recurrence or metastatic disease within 24 weeks of neoadjuvant/adjuvant therapy, it is considered as one line of systemic chemotherapy. (3) Therapies that can be performed at an earlier stage are chemotherapy in conjunction with molecular targeted drugs.
3. Expected survival after first dose of study drug \> 24 weeks.
4. At least one measurable lesion (≥ 10 mm) for imaging assessment.
5. ECOG scores 0 - 1.
6. Fresh pathological tissue specimens can be obtained
7. White blood cells (WBCs) ≥ 2.5×10\^9/L
* Platelets (PLT) ≥ 100×10\^9/L
* Hemoglobin, Blood (Hb) ≥ 9.0 g/dL
* MID ≥ 1.5×10\^9/L
* Lymphocyte (LY) ≥ 0.47×10\^9/L
* LY% ≥ 15%
8. Serum albumin (Alb) ≥ 30 g/L
9. Serum lipase (LPS) and serum amylase \< 1.5 ULN
10. Serum creatinine ≤ 1.5 ULN
11. Alanine aminotransferase (ALT) ≤ 2.5 ULN
* Aspartate aminotransferase (AST) ≤ 2.5 ULN
* If osseous metastasis or liver metastasis is developed and alkaline phosphatase • (ALP) \> 2.5 ULN, ALT and AST \< 1.5 ULN.
12. Serum total bilirubin (TBIL) ≤ 1.5 ULN
13. Prothrombin Time (PT): International Normalized Ratio (INR) \< 1.7.
* PT \< (ULN + 4) s
All test results should be within their normal ranges, and the patient is not receiving continuous supportive care.
Exclusion Criteria
1. Pregnant or lactating women.
2. HIV positive, HCV positive, HBV DNA copies ≥ 10\^3.
3. Uncontrolled active infection.
4. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
5. Allergic to immunotherapies and related drugs.
6. Untreated brain metastases or having symptoms of brain metastases.
7. Metastases to the lung: central tumor or multiple metastases.
8. Patients with heart disease for which treatment is needed or with poorly controlled hypertension.
9. Patients with unstable or active peptic ulcer or with alimentary tract hemorrhage.
10. Patients with previous organ transplantation or in preparation for organ transplantation.
11. Patients have undertaken major surgeries or have been badly injured 4 weeks before the study (blood collection), or will undertake major surgeries during the study.
12. The judgment of investigators that the patient is not able to or not willing to follow the instructions of the protocol.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stemirna Therapeutics
INDUSTRY
Changhai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bin Wang
Attending physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xianbao Zhan, Dr.
Role: STUDY_DIRECTOR
Chanhai hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changhai Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wang B, Peng X, Li J, Wang Y, Chen L, Wu M, Zhang Y, Wang W, Feng D, Tang S, Zhang L, Zhan X. Personalized mRNA vaccine combined with PD-1 inhibitor therapy in a patient with advanced esophageal squamous cell carcinoma. Am J Cancer Res. 2024 Aug 25;14(8):3896-3904. doi: 10.62347/NVFB3780. eCollection 2024.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHO-01002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.